Literature DB >> 33734425

VEGF-A/VEGF-B/VEGF-C expressions in non-hereditary, non-metastatic phaeochromocytoma.

Ichiro Abe1,2, Farhadul Islam3, Chung Yau Lo4, Victor Liew5, Suja Pillai1,6, Alfred K Lam1,7.   

Abstract

Vascular endothelial growth factor (VEGF) is important in pathogenesis of different cancers. The aim of this study is to investigate the relationships between different VEGFs and clinicopathological factors in patients with phaeochromocytomas. Twenty patients (10 men; 10 women) with non-hereditary, non-metastatic phaeochromocytomas were examined for VEGF mRNA expressions by polymerase chain reaction. The expressions were correlated with the clinical and pathological factors of the patients. In addition, mouse double minute 2 (MDM2) expression in these tumours were studied by immunohistochemistry. High expressions of VEGF-A, VEGF-B, and VEGF-C mRNA were detected in 11 (55%), 9 (45%), and 9 (45%) of the tumours respectively. High expression of VEGF-A in phaeochromocytomas was significantly correlated with the tumour size (p=0.025) but did not correlate with patients' age, gender, and tumour laterality. Besides, there was a trend of VEGF-A expression correlated with MDM2 expression (p=0.064). On the other hand, expressions of VEGF-B and VEGF-C were not significantly correlated with tumour size, patients' age, gender, tumour laterality, and MDM2 expression. In addition, high expressions of VEGF-B and VEGF-A were associated with increase of tumour size (p=0.042). Co-expression of different VEGFs did not correlate with MDM2 expression. To conclude, there is a role for VEGF-A/VEGF-B/VEGF-C in the pathogenesis of non-hereditary, non-metastatic phaeochromocytomas.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33734425     DOI: 10.14670/HH-18-329

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  44 in total

1.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis.

Authors:  G Bergers; R Brekken; G McMahon; T H Vu; T Itoh; K Tamaki; K Tanzawa; P Thorpe; S Itohara; Z Werb; D Hanahan
Journal:  Nat Cell Biol       Date:  2000-10       Impact factor: 28.824

Review 2.  Endothelial signaling during development.

Authors:  Ondine Cleaver; Douglas A Melton
Journal:  Nat Med       Date:  2003-06       Impact factor: 53.440

Review 3.  VEGF as a key mediator of angiogenesis in cancer.

Authors:  Peter Carmeliet
Journal:  Oncology       Date:  2005-11-21       Impact factor: 2.935

Review 4.  Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity.

Authors:  Patricia L M Dahia
Journal:  Nat Rev Cancer       Date:  2014-01-20       Impact factor: 60.716

Review 5.  Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma.

Authors:  E L Bravo
Journal:  Endocr Rev       Date:  1994-06       Impact factor: 19.871

6.  Differences in the actions of adrenaline and noradrenaline with regard to glucose intolerance in patients with pheochromocytoma.

Authors:  Ichiro Abe; Hideyuki Fujii; Hanako Ohishi; Kaoru Sugimoto; Midori Minezaki; Midori Nakagawa; Saori Takahara; Tadachika Kudo; Makiko Abe; Kenji Ohe; Toshihiko Yanase; Kunihisa Kobayashi
Journal:  Endocr J       Date:  2018-12-13       Impact factor: 2.349

7.  Pheochromocytoma crisis caused by Campylobacter fetus.

Authors:  Ichiro Abe; Masatoshi Nomura; Makiko Watanabe; Shingo Shimada; Michiko Kohno; Yayoi Matsuda; Masahiro Adachi; Hisaya Kawate; Keizo Ohnaka; Ryoichi Takayanagi
Journal:  Int J Urol       Date:  2012-01-06       Impact factor: 3.369

Review 8.  Molecular mechanisms and clinical applications of angiogenesis.

Authors:  Peter Carmeliet; Rakesh K Jain
Journal:  Nature       Date:  2011-05-19       Impact factor: 49.962

9.  Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis.

Authors:  Imke Albrecht; Lucie Kopfstein; Karin Strittmatter; Tibor Schomber; Annelie Falkevall; Carolina E Hagberg; Pascal Lorentz; Michael Jeltsch; Kari Alitalo; Ulf Eriksson; Gerhard Christofori; Kristian Pietras
Journal:  PLoS One       Date:  2010-11-24       Impact factor: 3.240

Review 10.  The clinical and therapeutic uses of MDM2 and PSMA and their potential interaction in aggressive cancers.

Authors:  Robyn Bradbury; Wen G Jiang; Yu-Xin Cui
Journal:  Biomark Med       Date:  2015-11-19       Impact factor: 2.851

View more
  1 in total

1.  Editorial: Recent Advances in Pheochromocytoma and Paraganglioma: Molecular Pathogenesis, Clinical Impacts, and Therapeutic Perspective.

Authors:  Farhadul Islam; Ichiro Abe; Suja Pillai; Robert A Smith; Alfred King-Yin Lam
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-23       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.